Darrell Tan

Darrell H. S. Tan is an infectious diseases physician and Clinician-Scientist at St. Michael’s Hospital, where he leads the Options Collaboratory in HIV/STI Treatment and Prevention Science (www.optionslab.ca). He is also an Associate Professor in the Department of Medicine and Institute of Health Policy, Management and Evaluation at the University of Toronto, with a cross-appointment in the Institute of Medical Science. His research focuses on clinical trials and implementation science in the areas of HIV prevention, HIV treatment and sexually transmitted infections (STIs) including mpox. Dr. Tan holds a Tier 2 Canada Research Chair in Biomedical HIV/STI Prevention, is Co-Lead of the Prevention and Testing Think Tank of the CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research, and is a member of the Governing Council of the International AIDS Society.

• PRIMP: a CIHR-funded implementation science project on optimizing the delivery of HIV pre-exposure prophylaxis (PrEP) among gay, bisexual and other men who have sex with men in urban Ontario and British Columbia

• The Future of PrEP is Now: a community-based research project on preparing for long-acting PrEP formulations.

• CAMP: The Canada-Africa Mpox Partnership is a CIHR-funded team grant conducting 1) observational research to understand clinical, epidemiologic and virologic dimensions of the mpox epidemic, 2) a clinical trial of antiviral therapy for mpox infection, and 3) evaluations of mpox vaccine safety and effectiveness in Canada. The team partners with investigators in Nigeria who are funded by IDRC to conduct parallel work in Nigeria.

• Updating Canadian Guidelines on HIV PrEP and PEP: Dr. Tan is co-chair of the diverse multidisciplinary panel which is updating guidelines using GRADE methodology as an initiative of the CTN+.

• DISCO: Dr. Tan is Co-PI of DISCO, a national open-label randomized trial of doxycycline PrEP and PEP for the prevention of bacterial STIs in GBM.

• HSV prevention: Dr. Tan is exploring the potential of antiviral drugs as PrEP and PEP against herpes simplex virus type 2 infection.

Other Appointments & Affiliations

• Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
• Assistant Professor, Department of Medicine, University of Toronto
• Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto
• Prevention & Testing Think Tank Co-lead, CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research (CTN+)
• Governing Council Member, International AIDS Society (IAS)